| REVIEW ARTICLE |
|
| Year : 2019 | Volume
: 15
| Issue : 4 | Page : 743-750 |
|
|
Pembrolizumab for the treatment of nonsmall cell lung cancer: Current status and future directions
Qin Qin1, Baosheng Li2
1 Department of Oncology, The Second Clinical Medical College, Jingzhou Central Hospital, Yangtze University, Jingzhou, Hubei 434020, China
2 Department of Radiation Oncology (Chest Section), Shandong Cancer Hospital and Institute, Shandong University, Jinan, Shandong 250117, China
Correspondence Address:
Baosheng Li
Department of Radiation Oncology (Chest Section), Shandong Cancer Hospital and Institute, Shandong University, Jinan, Shandong 250117
China
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/jcrt.JCRT_903_18
|
|
|
The development of inhibitors of immune checkpoints has revolutionized the treatment for a subset of patients with advanced nonsmall cell lung cancer (NSCLC), resulting in promising clinical outcomes and durable responses. Pembrolizumab, a humanized anti-programmed cell death-1 (PD-1) antibody, has been approved as a first-line treatment for patients with advanced NSCLC with PD-L1 expression of ≥50% and as a second-line treatment for PD-L1 expression of ≥1%. Pembrolizumab in combination with standard chemotherapy has shown better clinical outcomes than chemotherapy as a first-line therapy in patients with advanced NSCLC without targetable mutations, regardless of PD-L1 expression. In this review, we summarized the current indications of pembrolizumab for NSCLC, briefly described immune-relevant pneumonitis and discussed potential biomarkers to predict clinical efficacy.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
